Business
Virtual Tumour Clinical Contract
Virtual Tumour Clinical Contract.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 3847G Physiomics PLC 06 June 2013 \n \n\n \n \nPhysiomics plc\nThe Magdalen Centre\nThe Oxford Science Park\nRobert Robinson Avenue\nOxford\nOX4 4GA\nUK\n \nTel 01865 784980\nFax 08701 671931\n5th June 2013 \nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics signs contract for Virtual Tumour Clinical and data analysis services\n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with a biotechnology company to apply its new Virtual Tumour Clinical platform to their lead compound. The biotechnology company will pay an up-front technology access fee now and ongoing service fees as the project progresses. This represents the first commercial deal for Physiomics' flagship Virtual Tumour Clinical technology. The project will commence immediately.\nPhysiomics' emerging Virtual Tumour Clinical technology will be used in conjunction with traditional PK/PD techniques to guide the dosing and scheduling of the biotechnology company's lead molecule in the clinic.\n \nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are delighted to start the first commercial Virtual Tumour Clinical project. Each new project that we complete will allow us to improve and extend the model and make it applicable to more oncology projects in future.\"\nEnquiries:\n \nPhysiomics plc \nDr Mark Chadwick, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estim...